Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Star Combo Pharma's annualizedNet Income for the quarter that ended in Dec. 2025 was A$0.83 Mil.
Star Combo Pharma's average Total Assets over the quarter that ended in Dec. 2025 was A$47.72 Mil. Therefore, Star Combo Pharma's annualized ROA % for the quarter that ended in Dec. 2025 was 1.73%.
The historical rank and industry rank for Star Combo Pharma's ROA % or its related term are showing as below:
ASX:S66'
s ROA % Range Over the Past 10 Years
Min: -14.3 Med: -4.42 Max: 11.64
Current: 11.64
During the past 9 years, Star Combo Pharma's highest ROA % was 11.64%. The lowest was -14.30%. And the median was -4.42%.
ASX:S66's ROA % is ranked better than 87.02% of 1995
companies
in the Consumer Packaged Goods industry
Industry Median: 3.32
vs ASX:S66: 11.64
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Star Combo Pharma ROA % Related Terms
Star Combo Pharma ROA % Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma ROA % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's ROA % distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Star Combo Pharma (ASX:S66) has a ROA % of 1.73% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #259 out of 1995 companies in the Consumer Packaged Goods industry, placing it in the top 13%.
Is Star Combo Pharma's ROA % too high?
Star Combo Pharma's current ROA % is 1.73%. The Consumer Packaged Goods industry median ROA % is 3.32. Star Combo Pharma's value of 1.73% is 47.9% below this industry median. Based on the distribution chart, Star Combo Pharma ranks #259 out of 1995 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's ROA % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #259 out of 1995 companies for ROA %. This places Star Combo Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median ROA % is 3.32. Star Combo Pharma's value of 1.73% is 47.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Consumer Packaged Goods company?
The median ROA % among Consumer Packaged Goods companies is 3.32, based on 1,995 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current ROA % of 1.73% is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median ROA % is 3.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current ROA % is 1.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current ROA % is 1.73% and 47.9% below the Consumer Packaged Goods industry median of 3.32. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current ROA % is 1.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
ROA %: 1.73%
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 47.9% below the Consumer Packaged Goods median (#259 of 1995)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
